ArticleFrontiers in pharmacology2023

Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China.

Zhen Feng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.